Protherics - Doc re Resolutions Passed at AGM


Cheshire, UK--(Marketwire - July 25, 2008) -


Protherics PLC


Documents filed with the UK Listing Authority


London, UK; Brentwood, TN, US: 25 July 2008 - In accordance with LR
9.6.2, Protherics PLC ("Protherics" or the "Company"),
the international biopharmaceutical company focused on critical care
and cancer, has today forwarded for publication through the Document
Viewing Facility, copies of all resolutions passed under Special
business at the Company's Annual General Meeting held on 22 July
2008 as summarised below:


  - Approval of the Directors' Remuneration Report.

  - Renewal of Directors' authority to allot shares.

  - Renewal of Directors' authority to disapply pre-emption rights (in
    respect of up to 10 per cent. of the issued share capital of the
    Company).

  - Approval of amendments to the Company's Articles of Association 
    (the "New Articles").

  - Approval of the Protherics PLC 2008 Savings Related Share Option
    Scheme ("Sharesave Scheme").

  - Approval of amendment to the Protherics PLC 1996 Unapproved Share
    Option Scheme ("Unapproved Scheme").


Copies of the full text of the above Resolutions, together with copies
of the New Articles, the rules of the Sharesave Scheme and the
amendment to the Unapproved Scheme can be obtained from the United
Kingdom Listing Authority's Document Viewing Facility situated at the
Financial Services Authority, The North Colonnade, Canary Wharf, London
E14 5HS.


/ Ends /



For further information please contact:


Protherics 

Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510  

Julie Vickers, Company Secretary            +44 (0)1928 518010


Financial Dynamics - press enquiries

London: Ben Atwell, Lara Mott               +44 (0) 20 7831 3113 

New York: John Capodanno                    +1 212 850 5600



Or visit  www.protherics.com


                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com